SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:56S1 • FR0013154002
191.6 EUR
-6.05 (-3.06%)
Last: Jan 29, 2026, 07:00 PM
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. While showing a medium growth rate, 56S1 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- 56S1 had positive earnings in the past year.
- In the past year 56S1 had a positive cash flow from operations.
- 56S1 had positive earnings in each of the past 5 years.
- 56S1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of 56S1 (3.36%) is worse than 63.64% of its industry peers.
- The Return On Equity of 56S1 (6.55%) is comparable to the rest of the industry.
- 56S1 has a Return On Invested Capital (5.94%) which is in line with its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is in line with the industry average of 9.34%.
- The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
- Looking at the Profit Margin, with a value of 8.98%, 56S1 is in line with its industry, outperforming 54.55% of the companies in the same industry.
- 56S1's Profit Margin has declined in the last couple of years.
- 56S1 has a better Operating Margin (16.63%) than 63.64% of its industry peers.
- 56S1's Operating Margin has declined in the last couple of years.
- 56S1's Gross Margin of 45.64% is in line compared to the rest of the industry. 56S1 outperforms 54.55% of its industry peers.
- In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
- 56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- 56S1 has more shares outstanding than it did 1 year ago.
- 56S1 has more shares outstanding than it did 5 years ago.
- 56S1 has a better debt/assets ratio than last year.
2.2 Solvency
- 56S1 has an Altman-Z score of 4.21. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
- With a decent Altman-Z score value of 4.21, 56S1 is doing good in the industry, outperforming 77.27% of the companies in the same industry.
- 56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
- 56S1 has a Debt to FCF ratio of 6.84. This is comparable to the rest of the industry: 56S1 outperforms 45.45% of its industry peers.
- A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.50, 56S1 is in line with its industry, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.21 |
ROIC/WACC0.61
WACC9.69%
2.3 Liquidity
- A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.05, 56S1 is doing worse than 72.73% of the companies in the same industry.
- A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.50, 56S1 is doing worse than 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 35.11% over the past year.
- 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
- The Revenue has been growing slightly by 7.72% in the past year.
- The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
- Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
- Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 9.86% on average per year.
EPS Next Y29.12%
EPS Next 2Y23.48%
EPS Next 3Y22.85%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 44.45 indicates a quite expensive valuation of 56S1.
- Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 77.27% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.30. 56S1 is valued rather expensively when compared to this.
- With a Price/Forward Earnings ratio of 35.90, 56S1 can be considered very expensive at the moment.
- 56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 72.73% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of 56S1 to the average of the S&P500 Index (25.57), we can say 56S1 is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.45 | ||
| Fwd PE | 35.9 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 56S1 is valued a bit more expensive than 77.27% of the companies in the same industry.
- The rest of the industry has a similar Price/Free Cash Flow ratio as 56S1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.78 | ||
| EV/EBITDA | 25.87 |
4.3 Compensation for Growth
- 56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as 56S1's earnings are expected to grow with 22.85% in the coming years.
PEG (NY)1.53
PEG (5Y)10.6
EPS Next 2Y23.48%
EPS Next 3Y22.85%
5. Dividend
5.1 Amount
- 56S1 has a yearly dividend return of 0.36%, which is pretty low.
- 56S1's Dividend Yield is comparable with the industry average which is at 0.48.
- With a Dividend Yield of 0.36, 56S1 pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
5.2 History
- The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- 56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.37%
EPS Next 2Y23.48%
EPS Next 3Y22.85%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 44.45 and the Price/Book (PB) ratio is 4.62.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.12% in the next year.